Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846214 | 0.82 | NAALAD2 (0.33) | — | |
| SCHEMBL2841410 | 0.81 | HMGCR (0.35) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL929910 | 0.76 | HMGCR (0.41) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL29796843 | 0.72 | — | — | |
| SCHEMBL2847763 | 0.71 | NAALAD2 (0.33) | TSHRHIF1A | |
| SCHEMBL6347557 | 0.71 | — | — | |
| SCHEMBL3952021 | 0.71 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL17582794 | 0.66 | CYP2C19 (0.51) | CHRM1CYP2D6CYP2C19HIF1AKDM4E | |
| SCHEMBL17582871 | 0.66 | CYP2C19 (0.51) | CHRM1CYP2D6CYP2C19HIF1AKDM4E | |
| SCHEMBL21580243 | 0.66 | CYP2C19 (0.51) | CHRM1CYP2D6CYP2C19HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796246-B2 | 9, 10-secopregnane derivative and pharmaceutical | NIPPON SHINYAKU CO., LTD. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20100130454-A1 | 9,10-SECOPREGNANE DERIVATIVES AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100016263-A1 | 9, 10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1829860-A1 | 9,10-SECOPREGNANE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130454-A1 | 9,10-SECOPREGNANE DERIVATIVES AND MEDICINE | VDR, CYP2R1, CYP24A1 | HMGCR 367/4885CHRM1 403/4885TBXA2R 372/4885 |
| US-20100016263-A1 | 9, 10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL | CYP2R1, VDR, CYP24A1 | HMGCR 309/4885CHRM1 500/4885TBXA2R 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.